Article
Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions - 10 Apr 2023
Lee Seung Hun, Jeong Young-Hoon, Hong David, Choi Ki Hong, Lee Joo Myung, Park Taek Kyu, Yang Jeong Hoon, Hahn Joo-Yong, Choi Seung-Hyuck, Gwon Hyeon-Cheol, Jeong Myung Ho, Kim Byeong-Keuk, Joo Hyung Joon, Chang Kiyuk, Park Yongwhi, Ahn Sung Gyun, Suh Jung-Won, Lee Sang Yeub, Cho Jung Rae, Her Ae-Young, Kim Hyo-Soo, Kim Moo Hyun, Lim Do-Sun, Shin Eun-Seok, Song Young Bin
Abstract excerpt
BACKGROUND: Although there is a growing body of evidence that CYP2C19 genotyping can be beneficial when considering treatment with clopidogrel after percutaneous coronary intervention (PCI), whether a genotype-guided strategy can be generally adopted in routine practice remains unclear among East Asians. OBJECTIVES: This study sought to investigate long-term outcomes of patients undergoing clopidogrel-based...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
